当前位置:首页 - 行情中心 - 近岸蛋白(688137) - 财务分析 - 利润表

近岸蛋白

(688137)

  

流通市值:13.03亿  总市值:27.98亿
流通股本:3267.54万   总股本:7017.54万

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入111,854,902.4372,094,559.1433,444,619.29127,555,134.78
  营业收入111,854,902.4372,094,559.1433,444,619.29127,555,134.78
二、营业总成本131,176,781.2984,803,092.5741,376,150.08166,495,773.97
  营业成本39,328,137.4225,614,277.912,622,698.2847,989,594.78
  税金及附加1,060,484.39535,546.95295,607.191,451,274.68
  销售费用40,258,262.126,113,512.5912,430,941.9951,933,890.07
  管理费用32,290,964.8421,934,529.4110,660,333.2249,153,756.32
  研发费用40,248,363.7126,101,953.2913,318,794.249,922,930.62
  财务费用-22,009,431.17-15,496,727.57-7,952,224.8-33,955,672.5
  其中:利息费用1,993,226.521,387,729.81760,243.023,587,125.11
  其中:利息收入24,774,916.3817,216,346.278,820,335.2336,906,796.53
三、其他经营收益
  加:公允价值变动收益----1,804,926.16
  加:投资收益267,479.91267,479.91267,479.914,569,887.11
  资产处置收益731,409.51731,409.51-141,603.68
  资产减值损失(新)-21,976,820.24-18,127,681.15-8,321,843.97-32,094,508.76
  信用减值损失(新)1,283,983.32827,598.9357,960.39-2,448,524.63
  其他收益881,071.31455,821.31374,528.2817,497,032.88
四、营业利润-38,134,755.05-28,553,904.92-15,553,406.18-53,080,075.07
  加:营业外收入18,846.8317,046.8511,480.248,271.63
  减:营业外支出386,273.79381,037.07279,966.861,186,467.8
五、利润总额-38,502,182.01-28,917,895.14-15,821,892.84-54,218,271.24
  减:所得税费用-9,642,913.51-4,694,324.32-4,013,489.43198,010.86
六、净利润-28,859,268.5-24,223,570.82-11,808,403.41-54,416,282.1
(一)按经营持续性分类
  持续经营净利润-28,859,268.5-24,223,570.82-11,808,403.41-54,416,282.1
(二)按所有权归属分类
  归属于母公司股东的净利润-28,859,268.5-24,223,570.82-11,808,403.41-54,416,282.1
  扣除非经常损益后的净利润-32,639,345.14-26,684,693.64-12,404,641.19-71,748,588.94
七、每股收益
  (一)基本每股收益-0.41-0.35-0.17-0.78
  (二)稀释每股收益-0.41-0.35-0.17-0.78
八、其他综合收益41,526.7612,987.8221,986.91-23,123.4
  归属于母公司股东的其他综合收益41,526.7612,987.8221,986.91-23,123.4
九、综合收益总额-28,817,741.74-24,210,583-11,786,416.5-54,439,405.5
  归属于母公司股东的综合收益总额-28,817,741.74-24,210,583-11,786,416.5-54,439,405.5
公告日期2025-10-302025-08-282025-04-292025-04-29
审计意见(境内)标准无保留意见
TOP↑